Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Mander

Showing results (11-20 of 84) with videos related to

Pageof 9
Sort By:
Contemporary Clinical Trials|June 3, 2021
Accounting for variation in the required sample size in the design of group-sequential trialsMichael J Grayling, Adrian P Mander
BMC Medical Research Methodology|January 30, 2019
Re-formulating Gehan's design as a flexible two-stage single-arm trialMichael J Grayling, Adrian P Mander
Pharmaceutical Statistics|November 27, 2015
Do single-arm trials have a role in drug development plans incorporating randomised trials?Michael J Grayling, Adrian P Mander
Journal of Biopharmaceutical Statistics|June 2, 2012
Minimizing the maximum expected sample size in two-stage Phase II clinical trials with continuous outcomesJames M S Wason, Adrian P Mander
Statistical Methods in Medical Research|December 20, 2011
The choice of test in phase II cancer trials assessing continuous tumour shrinkage when complete responses are expectedJames M S Wason, Adrian P Mander
The New Zealand Medical Journal|November 10, 1982
Bioavailability and half-life of two preparations of flucloxacillinD M Paton, P Mander, R J Avery
Pharmaceutical Statistics|July 29, 2024
Efficient Study Design and Analysis of Longitudinal Dose-Response Data Using Fractional PolynomialsBenjamin F Hartley, Dave Lunn, Adrian P Mander
Journal of Biopharmaceutical Statistics|January 25, 2022
A stochastically curtailed single-arm phase II trial design for binary outcomesMartin Law, Michael J Grayling, Adrian P Mander
Pharmaceutical Statistics|August 30, 2020
A stochastically curtailed two-arm randomised phase II trial design for binary outcomesMartin Law, Michael J Grayling, Adrian P Mander
Trials|December 4, 2019
Sample size re-estimation in crossover trials: application to the AIM HY-INFORM studyJulie Wych, Michael J Grayling, Adrian P Mander
Pageof 9

Showing results (11-20 of 84) with videos related to

Sort By:
Pageof 9
Contemporary Clinical Trials|June 3, 2021
Accounting for variation in the required sample size in the design of group-sequential trialsMichael J Grayling, Adrian P Mander
BMC Medical Research Methodology|January 30, 2019
Re-formulating Gehan's design as a flexible two-stage single-arm trialMichael J Grayling, Adrian P Mander
Pharmaceutical Statistics|November 27, 2015
Do single-arm trials have a role in drug development plans incorporating randomised trials?Michael J Grayling, Adrian P Mander
Journal of Biopharmaceutical Statistics|June 2, 2012
Minimizing the maximum expected sample size in two-stage Phase II clinical trials with continuous outcomesJames M S Wason, Adrian P Mander
Statistical Methods in Medical Research|December 20, 2011
The choice of test in phase II cancer trials assessing continuous tumour shrinkage when complete responses are expectedJames M S Wason, Adrian P Mander
The New Zealand Medical Journal|November 10, 1982
Bioavailability and half-life of two preparations of flucloxacillinD M Paton, P Mander, R J Avery
Pharmaceutical Statistics|July 29, 2024
Efficient Study Design and Analysis of Longitudinal Dose-Response Data Using Fractional PolynomialsBenjamin F Hartley, Dave Lunn, Adrian P Mander
Journal of Biopharmaceutical Statistics|January 25, 2022
A stochastically curtailed single-arm phase II trial design for binary outcomesMartin Law, Michael J Grayling, Adrian P Mander
Pharmaceutical Statistics|August 30, 2020
A stochastically curtailed two-arm randomised phase II trial design for binary outcomesMartin Law, Michael J Grayling, Adrian P Mander
Trials|December 4, 2019
Sample size re-estimation in crossover trials: application to the AIM HY-INFORM studyJulie Wych, Michael J Grayling, Adrian P Mander
Pageof 9